AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9640158
Drug: Etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.3 mg kg‐1 (AE‐R group)
Trial: 3055394
Drug: Perioperative parenteral
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative parenteral cefoxitin (Group A)
Trial: 3055394
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral neomycin and erythromycin plus perioperative cefoxitin (Group B)
Trial: 3055394
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (cefoxitin) with rectal resections
Trial: 3055394
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (neomycin and erythromycin plus cefoxitin) with rectal resections
Trial: 3055394
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A patients with longer rectal operations
Trial: 3055394
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with rectal resection and operative times of 215 minutes or more
Trial: 30920631
Drug: Streptococcus salivarius
RxNorm normalized name: Streptococcus salivarius
DrugBank: Streptococcus salivarius (DB19274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray, 2 puffs per nostril twice a day for a week for 3 months
Trial: 11323362
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine 2 mg/mL with fentanyl 2 microg/mL (R + F)
Trial: 11323362
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine 2 mg/mL without fentanyl (R)
Trial: 8394796
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg administered at 7 AM
Trial: 8394796
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg administered at 7 PM
Trial: 3205554
Drug: 3% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% prilocaine (Citanest) containing 0.03 IU/ml felypressin
Trial: 28468736
Drug: Nicotinamide 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide 500 mg/daily
Trial: 18492867
Drug: Intensive renal-replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive renal-replacement therapy (intermittent hemodialysis six times per week, sustained low-efficiency dialysis, continuous venovenous hemodiafiltration at 35 ml/kg/hour)
Trial: 18492867
Drug: Less-intensive renal-replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-intensive renal-replacement therapy (intermittent hemodialysis three times per week, continuous renal-replacement therapy at 20 ml/kg/hour)
Trial: 18492867
Drug: Intensive renal-replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive renal-replacement therapy
Trial: 18492867
Drug: Less-intensive renal-replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-intensive renal-replacement therapy
Trial: 8120158
Drug: Pulse-loading (P-L)
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse-loading (P-L) group received 150 and 200 mg of clomipramine (CMI) on two consecutive evenings, then placebo for 8 days
Trial: 8120158
Drug: Traditional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional group began at 50 mg of CMI, followed by gradual increases every second day until 200 mg was reached
Trial: 8120158
Drug: Pulse-loading (P-L)
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse-loading (P-L) group
Trial: 3321413
Drug: LAF +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAF + PSA (decontamination, isolation in a laminar air flow room and prophylactic systemic antibiotics)
Trial: 3321413
Drug: PSA (prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA (prophylactic systemic antibiotics in a conventional hospital room)
Trial: 25645191
Drug: Essential-oil extract
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential-oil extract of Cretan aromatic plants (0.5ml soft gel capsules, twice a day for 7 days)
Trial: 25645191
Drug: Placebo (0.5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5ml olive oil in soft gel capsules)
Trial: 11559718
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg daily for 4 months
Trial: 11559718
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg daily for 4 months
Trial: 3665523
Drug: Calcium entry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium entry blocker nicardipine
Trial: 31378952
Drug: Levodopa Benserazide
RxNorm normalized name: benserazide / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa Benserazide (LDB) generic preparation (Teva Italia)
Trial: 26477840
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab given monthly
Trial: 20691834
Drug: rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (10 mg/d)
Trial: 7628184
Drug: Omeprazole, 40
RxNorm normalized name: Omeprazole, 40 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 40 mg/day
Trial: 24912456
Drug: STEPPS (Systems
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEPPS (Systems Training for Emotional Predictability and Problem Solving) added to treatment as usual (TAU) for BD
Trial: 18826866
Drug: Deferasirox 20
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox 20 mg/kg coadministered with digoxin
Trial: 12776949
Drug: Normal-dosage Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dosage Group (3 mg/kg of heparin)
Trial: 10979947
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg/d) for 75 days after BMT
Trial: 27739334
Drug: Self-referral to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-referral to inpatient treatment (SRIT)
Trial: 18274222
Drug: Low-dose exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exercise (20 min/day, 5 days/week for 15 weeks)
Trial: 18274222
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise (40 min/day, 5 days/week for 15 weeks)
Trial: 11384079
Drug: Fosinopril (FOS)
DrugBank: Fosinopril (DB00492)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosinopril (FOS) 10 mg
Trial: 11384079
Drug: Captopril (CAP)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CAP) 6.25 mg
Trial: 7907184
Drug: Maintaining the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintaining the same dose of the neuroleptic over an extended trial
Trial: 7907184
Drug: Significantly increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Significantly increasing the dose of the same neuroleptic
Trial: 6108299
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of lorazepam
Trial: 30885824
Drug: No Erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Erythropoietin (EPO) treatment (Control)
Trial: 28665874
Drug: Single-injection PVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection PVB at T3-T4 level with 25 mL of 0.5% ropivacaine and 4 subcutaneous sham injections
Trial: 28665874
Drug: Multiple-injection PVB
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple-injection PVB from T1 to T5 level with 5 mL of 0.5% ropivacaine injected at each level
Trial: 25005327
Drug: golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 50 mg + MTX
Trial: 23861303
Drug: golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 100 mg + MTX (in patients with CRP >1.0 mg/dl)
Trial: 15113632
Drug: Breast‐fed and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast‐fed and 1‐ml 30% glucose
Trial: 15113632
Drug: Fasting and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting and 1‐ml 30% glucose
Trial: 9333792
Drug: Bilevel therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilevel therapy with a fixed inspiratory to expiratory pressure ratio of 1:0.6
Trial: 8498624
Drug: 11-lesson curriculum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-lesson curriculum focused on drug resistance skills
Trial: 23717119
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng (4,500 mg daily for 2 weeks)
Trial: 14698695
Drug: Conservative AED
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative AED treatment
Trial: 11270479
Drug: Melatonin plus
RxNorm normalized name: Nature's Truth Melatonin Plus L-Theanine 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin plus 5-methoxytryptamine (1 mg/day orally in the early afternoon)
Trial: 9252932
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot (3.75 mg once monthly)
Trial: 24282477
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg caffeine
Trial: 12618736
Drug: Drugs (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs (90 patients)
Trial: 10883557
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), 7-week group intervention
Trial: 6431211
Drug: Milacemide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 400 mg
Trial: 6431211
Drug: Milacemide 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 800 mg
Trial: 6431211
Drug: Milacemide 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide 1600 mg
Trial: 6431211
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 600 mg
Trial: 3370078
Drug: Piracetam 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam 1600 mg
Trial: 30788925
Drug: Dicycle (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicycle (Group B: dexamethasone 40 mg once a day, from day 1 to day 4, day 15 to day 18)
Trial: 30788925
Drug: Tri-cycle (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-cycle (Group C: dexamethasone 40 mg once a day, from day 1 to day 4, day 15 to day 18, day 29 to day 32)
Trial: 25171270
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein intake (DPI) above the median (mean DPI of >1 g/kg)
Trial: 23207335
Drug: Entecavir monotherapy
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir monotherapy for 3 years
Trial: 23207335
Drug: Control (non‐antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non‐antiviral treatment)
Trial: 9708959
Drug: Tolcapone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (both doses)
Trial: 2309541
Drug: Midazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4 mg/kg rectally as premedication
Trial: 6804244
Drug: desmethyldiazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: desmethyldiazepam (20 mg/kg/day) for one week
Trial: 31519550
Drug: Very-low-phosphate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-phosphate diet (phosphate-to-protein ratio of 8 mg/g)
Trial: 31519550
Drug: Low-phosphate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-phosphate diet (phosphate-to-protein ratio of 10 mg/g)
Trial: 29280664
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement with stevia and L-carnitine
Trial: 24679851
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied to the irradiated side of the face after surgery
Trial: 20062928
Drug: DZ-697b 360
RxNorm normalized name: DA-697b
DrugBank: DA-697b (DB06001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZ-697b 360 mg
Trial: 7755941
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg verapamil (V) twice a day
Trial: 7755941
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (T and V)
Trial: 15107971
Drug: Everolimus 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 1.5 mg
Trial: 15107971
Drug: Everolimus 3
RxNorm normalized name: everolimus 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 3 mg
Trial: 29084336
Drug: s-lactam plus
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Docusoft-S Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s-lactam plus macrolide combination therapy
Trial: 29084336
Drug: s-lactam monotherapy
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s-lactam monotherapy
Trial: 26114161
Drug: Experimental therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapy (bevacizumab)
Trial: 21723554
Drug: Active tablets
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tablets containing 3.4 mg of VPP and IPP
Trial: 16752625
Drug: Mandibular overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdentures retained by 2 endosseous implants
Trial: 21195291
Drug: Carthami-Semen (CS)
RxNorm normalized name: Hippocastani semen
DrugBank: Horse chestnut (DB13195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carthami-Semen (CS) acupuncture point injection
Trial: 21195291
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) acupuncture point injection
Trial: 19446152
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate (300 mg loading dose, 75 mg/d maintenance dose)
Trial: 19446152
Drug: Clopidogrel bisulfate
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel bisulfate (300 mg loading dose, 75 mg/d maintenance dose)
Trial: 19446152
Drug: Both clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both clopidogrel preparations
Trial: 15628250
Drug: Ultrasound with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound with standard gel
Trial: 9252710
Drug: Lentinan administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lentinan administration
Trial: 31090212
Drug: Commonly prescribed
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commonly prescribed drugs
Trial: 27458307
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus ipilimumab
Trial: 26305052
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 30 days
Trial: 26305052
Drug: Resveratrol 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 75 mg twice daily for 30 days
Trial: 23686786
Drug: Caffeine/Ephedrine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine/Ephedrine (200 mg caffeine/20 mg ephedrine t.i.d.)
Trial: 17159824
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen therapy (2 mg daily)
Trial: 15223106
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and transdermal)
Trial: 29397354
Drug: Napabucasin 480
RxNorm normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Napabucasin 480 mg taken orally every 12 hours
Trial: 24930587
Drug: Chlorophyll-a photodynamic
RxNorm normalized name: CHLOROPHYLL A
DrugBank: Chlorophyll A (DB02133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorophyll-a photodynamic therapy (8 treatment sessions over 4 weeks)
Trial: 3965439
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of haloperidol
Trial: 6356911
Drug: Aspirin, Indomethacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, Indomethacin, Placebo
Trial: 26911397
Drug: Adherence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence therapy (six sessions in addition to usual care)
Trial: 19899321
Drug: noMR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: noMR group (n = 40) - only an intubation dose of cisatracurium (0.15 mg kg(‐1)) was administered
Trial: 19899321
Drug: MR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR group (n = 40) - continuous infusion of muscle relaxant added to the intubation dose
Trial: 17642451
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Group B, n=30)
Trial: 15100698
Drug: Ketamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine at 50 ng/ml plasma concentration
Trial: 15100698
Drug: Ketamine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine at 100 ng/ml plasma concentration
Trial: 11246934
Drug: Anhydrous crystalline
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 12 weeks (study Alpha)
Trial: 11246934
Drug: Anhydrous crystalline
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 24 weeks (study Omega)
Trial: 9674458
Drug: Sparfloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin, 400 mg on day 1, then 200 mg once daily for 10 days
Trial: 8033429
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy and/or relapse
Trial: 23642943
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 placebo soft gels)
Trial: 21091683
Drug: Topical nadifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nadifloxacin 1% cream
Trial: 21091683
Drug: Topical erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical erythromycin 4% gel
Trial: 18206946
Drug: Alarm treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alarm treatment following pretreatment with antimuscarinics and/or holding exercises
Trial: 17067352
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment
Trial: 9333973
Drug: Orthopedic Horseback‐Riding‐Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthopedic Horseback‐Riding‐Therapy (OHRT)
Trial: 8500515
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg bumethanide at 0800 and 1200 (treatment 1)
Trial: 8500515
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg bumethanide at 0800, 1200, 1800, 2200 (treatment 2)
Trial: 8500515
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bendroflumethiazide at 0800 and 1800 (treatment 3)
Trial: 27584567
Drug: Intravenous β-blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous β-blockers
Trial: 1595785
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg daily) plus low-dose aspirin
Trial: 3883732
Drug: oral molsidomine
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral molsidomine (Corvaton, 6 mg/day)